Skip to main content
    I

    Ionis Pharmaceuticals Inc (IONS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.01
    -1.05 (-3.61%)

    Market Cap: $4.84B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ionis Pharmaceuticals Inc (IONS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Ionis Pharmaceuticals reported revenue of $943.71M for the fiscal year ended Dec 31, 2025, up 33.8% from the year before. That year, net income was -$381.39M with a net margin of -40.4%, operating cash flow was -$268.58M and free cash flow was -$320.03M. The quarter ended Sep 30, 2026 had revenue of $242.72M and net income of -$109.97M.

    Revenue and Margins

    The operating margin was -40.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $372.78M, a compound annual rate of 10.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$943.71M+33.8%98.3%-40.4%-40.4%
    Dec 2024$705.14M-10.5%98.4%-67.4%-64.4%
    Dec 2023$787.65M+34.1%98.8%-44.9%-46.5%
    Dec 2022$587.37M-27.5%97.6%-69.8%-45.9%
    Dec 2021$810.46M+11.1%98.7%-3.7%-3.5%
    Dec 2020$729.26M-35.0%98.4%-23.6%-65.8%
    Dec 2019$1.12B+87.2%99.6%32.6%25.6%
    Dec 2018$599.67M+16.6%99.7%-10.2%35.9%
    Dec 2017$514.18M+37.9%100.0%6.0%-2.1%
    Dec 2016$372.78MN/A100.0%-5.4%-16.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$943.71M$705.14M$787.65M$587.37M$810.46M$729.26M$1.12B$599.67M$514.18M$372.78M
    Cost of revenue$15.91M$11.21M$9.13M$14.12M$10.84M$11.95M$4.38M$1.82M$0$0
    Gross profit$927.80M$693.92M$778.51M$573.25M$799.61M$717.32M$1.12B$597.85M$514.18M$372.78M
    Research and development$915.62M$901.53M$899.63M$833.15M$643.45M$535.08M$465.69M$414.60M$374.64M$344.32M
    Operating income-$381.68M-$475.08M-$353.73M-$410.19M-$30.19M-$172.08M$365.88M-$61.37M$31.05M-$20.16M
    Net income-$381.39M-$453.90M-$366.29M-$269.72M-$28.60M-$479.74M$287.26M$214.99M-$10.78M-$60.40M
    EBITDAN/AN/A-$339.69M-$232.99M$2.35M-$140.21M$376.65M-$14.87M$71.11M$27.49M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$242.72M$267.95M$246.09M$203.33M$156.72M$452.05M$131.61M$226.58M$133.81M$225.25M$119.50M$324.50M
    Gross profit$239.40M$265.21M$243.11M$195.37M$154.38M$447.90M$130.15M$222.75M$132.74M$221.09M$117.35M$321.44M
    Operating income-$130.70M-$102.29M-$117.42M-$214.46M-$160.18M$139.82M-$146.86M-$110.82M-$148.66M-$66.09M-$149.51M-$6.12M
    Net income-$109.97M-$114.65M-$92.53M-$229.39M-$128.61M$123.55M-$146.94M-$104.35M-$140.48M-$66.27M-$142.80M-$9.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $1.75B exceeded cash and equivalents by $1.38B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$3.52B$3.00B$2.99B$2.53B$2.61B$2.39B$3.23B$2.67B$1.32B$912.47M
    Current assets$2.99B$2.62B$2.64B$2.20B$2.35B$2.13B$2.72B$2.21B$1.17B$797.93M
    Cash and equivalents$372.26M$242.08M$399.27M$276.47M$869.19M$397.66M$683.29M$278.82M$129.63M$84.69M
    Total liabilities$3.03B$2.42B$2.60B$1.96B$1.84B$1.65B$1.55B$1.48B$957.49M$812.90M
    Short-term debt$431.95M$0$44.33M$0$3.53M$308.81M$0$13.75M$1.62M$1.19M
    Long-term debt$1.32B$1.25B$1.23B$1.18B$1.22B$600.12M$769.96M$628.06M$592.88M$500.51M
    Shareholder equity$489.09M$588.35M$386.69M$572.89M$771.74M$743.28M$1.47B$1.05B$281.01M$99.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.91B$2.99B$3.45B$3.52B$3.03B$2.99B$2.81B$3.00B$3.08B$2.69B$2.76B$2.76B
    Total liabilities$2.52B$2.55B$2.96B$3.03B$2.42B$2.35B$2.34B$2.42B$2.42B$2.43B$2.47B$2.47B
    Cash and equivalents$296.30M$350.06M$173.38M$372.26M$338.34M$297.30M$264.19M$242.08M$334.61M$293.99M$348.89M$348.89M
    Shareholder equity$393.64M$439.74M$491.41M$489.09M$617.97M$631.72M$475.73M$588.35M$662.47M$263.70M$296.51M$296.51M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$268.58M-$500.95M-$307.51M-$274.37M$30.80M$35.89M$345.63M$602.91M$174.15M-$112.11M
    Capital expenditures$51.44M$45.28M$23.80M$15.72M$11.96M$35.12M$30.91M$17.65M$37.86M$11.53M
    Free cash flow-$320.03M-$546.23M-$331.32M-$290.09M$18.84M$772.00K$314.72M$585.25M$136.29M-$123.63M
    Dividends paidN/AN/AN/A$10.95M$16.73M$544.69M$0$0$0$0
    Share repurchasesN/AN/AN/AN/AN/A$90.55M$34.39M$0$2.04M$818.00K
    Investing cash flow-$277.78M-$134.03M-$214.13M-$262.64M$194.91M$274.48M-$41.27M-$929.56M-$358.29M$56.60M
    Financing cash flow$675.84M$478.06M$644.08M-$55.30M$245.93M-$596.61M$100.02M$475.87M$229.09M$11.39M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$179.42M$565.53M-$792.82M-$137.71M-$131.44M$151.34M-$150.78M-$116.14M-$114.99M-$119.88M-$149.94M$32.87M
    Capital expenditures$12.71M$16.08M$21.76M$21.29M$5.27M$12.30M$12.58M$25.50M$9.06M$6.23M$4.49M$819.00K
    Free cash flow-$192.13M$549.45M-$814.58M-$159.00M-$136.71M$139.03M-$163.35M-$141.64M-$124.05M-$126.11M-$154.43M$32.05M
    Last 12 quarters

    Frequently Asked Questions About IONS

    What is Ionis Pharmaceuticals' annual revenue?

    Ionis Pharmaceuticals reported revenue of $943.71M for the fiscal year ended Dec 31, 2025.

    How fast is Ionis Pharmaceuticals' revenue growing?

    Revenue was up 33.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.1%.

    Is Ionis Pharmaceuticals profitable?

    No. Ionis Pharmaceuticals reported net income of -$381.39M for the fiscal year ended Dec 31, 2025, with a net margin of -40.4%.

    How much free cash flow does IONS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$268.58M minus capital expenditures of $51.44M produced free cash flow of -$320.03M.

    How much debt does Ionis Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.32B, short-term debt of $431.95M and cash and equivalents of $372.26M.